CHCWM – Cancer & Hematology Centers of West Michigan

R6569-ONC-1933 (Regeneron)

R6569-ONC-1933 (Regeneron)

Description:  A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies. 

Mechanism of Action:  Fully Human Monoclonal Antibody Targeting GITR plus cemiplimab (PD1 inhibitor)

Target Patient Population:  All Solid Tumors, patients are put on a wait list

Study Design:  Drug is administered IV every 3 weeks.